Applied DNA Sciences Shares Triples After Monkeypox Diagnostic Test Update

Applied DNA Sciences Shares Triples After Monkeypox Diagnostic Test Update
  • Applied DNA Sciences Inc APDN has initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus. 
  • The test has been developed as an NYSDOH Laboratory Developed Test (LDT) type. 
  • If Applied DNA validates the test, a validation package will be submitted to the New York State Department of Health (NYSDOH) for approval. 
  • If approved, the test will be used to power ADCL's monkeypox testing services.
  • Applied DNA's monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR. 
  • California Governor Gavin Newsom declared a state of emergency over the monkeypox.
  • California confirmed 827 monkeypox cases, the second-largest state tally after the 1,390 infections documented in New York, according to the U.S. Centers for Disease Control and Prevention.
  • Price Action: APDN shares are up 236.3% at $2.29 during the market session on the last check Tuesday.

Posted In: BriefsMonkeypoxwhy it's movingNewsPenny StocksHealth CareMoversTrading IdeasGeneral